Hesse Andrea, Kosmides Daniela, Kontermann Roland E, Nettelbeck Dirk M
Virotherapy Lab, Department of Dermatology, University Hospital Erlasngen, Hartmannstrasse 14, Erlangen, Germany.
J Virol. 2007 Mar;81(6):2688-99. doi: 10.1128/JVI.02722-06. Epub 2006 Dec 27.
Recombinant adenoviruses have emerged as promising agents in therapeutic gene transfer, genetic vaccination, and viral oncolysis. Therapeutic applications of adenoviruses, however, would benefit substantially from targeted virus cell entry, for example, into cancer or immune cells, as opposed to the broad tropism that adenoviruses naturally possess. Such tropism modification of adenoviruses requires the deletion of their natural cell binding properties and the incorporation of cell binding ligands. The short fibers of subgroup F adenoviruses have recently been suggested as a tool for genetic adenovirus detargeting based on the reduced infectivity of corresponding adenovectors with chimeric fibers in vitro and in vivo. The goal of our study was to determine functional insertion sites for peptide ligands in the adenovirus serotype 41 (Ad41) short fiber knob. With a model peptide, CDCRGDCFC, we could demonstrate that ligand incorporation into three of five analyzed loops of the knob, namely, EG, HI, and IJ, is feasible without a loss of fiber trimerization. The resulting adenovectors showed enhanced infectivity for various cell types, which was superior to that of viruses with the same peptide fused to the fiber C terminus. Strategies to further augment gene transfer efficacy by extension of the fiber shaft, insertion of tandem copies of the ligand peptide, or extension of the ligand-flanking linkers failed, indicating that precise ligand positioning is pivotal. Our study establishes that internal ligand incorporation into a short-shafted adenovirus fiber is feasible and suggests the Ad41 short fiber with ligand insertion into the top (IJ loop) or side (EG and HI loops) of the knob domain as a novel platform for genetic targeting of therapeutic adenoviruses.
重组腺病毒已成为治疗性基因转移、基因疫苗接种和病毒溶瘤中有前景的媒介。然而,腺病毒的治疗应用将从靶向病毒进入细胞中大幅受益,例如进入癌细胞或免疫细胞,这与腺病毒天然具有的广泛嗜性相反。腺病毒的这种嗜性修饰需要删除其天然细胞结合特性并引入细胞结合配体。最近,F亚组腺病毒的短纤维被认为是一种用于腺病毒去靶向的工具,这是基于相应嵌合纤维腺病毒载体在体外和体内的感染性降低。我们研究的目的是确定腺病毒血清型41(Ad41)短纤维钮扣中肽配体的功能插入位点。使用模型肽CDCRGDCFC,我们可以证明将配体掺入钮扣五个分析环中的三个环,即EG、HI和IJ环是可行的,且不会导致纤维三聚化丧失。所得的腺病毒载体对各种细胞类型显示出增强的感染性,优于相同肽融合到纤维C末端的病毒。通过延长纤维杆、插入配体肽的串联拷贝或延长配体侧翼连接子来进一步提高基因转移效率的策略均失败了,这表明精确的配体定位至关重要。我们的研究证实将内部配体掺入短杆腺病毒纤维是可行的,并表明将配体插入钮扣结构域顶部(IJ环)或侧面(EG和HI环)的Ad41短纤维可作为治疗性腺病毒基因靶向的新平台。